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Abstract
Introduction: An impactful clinical trial will have real-life benefits for patients and society beyond the academic
environment. This study analyses case studies of cancer trials to understand how impact is evidenced for cancer
trials and how impact evaluation can be more routinely adopted and improved.
Methods: The United Kingdom (UK) Government allocates research funding to higher-education institutions based
on an assessment of the institutions’ previous research efforts, in an exercise known as the Research Excellence
Framework (REF). In addition to each institution’s journal publications and research environment, for the first time in
2014, allocation of funding was also dependent on an evaluation of the wider, societal impact of research
conducted. In the REF2014, impact assessment was performed by evaluation of impact case studies. In this study,
case studies (n = 6637) submitted by institutions for the REF2014 were accessed and those focussing on cancer
trials were identified. Manual content analysis was then used to assess the characteristics of the cancer trials
discussed in the case studies, the impact described and the methods used by institutions to demonstrate impact.
Results: Forty-six case studies describing 106 individual cancer trials were identified. The majority were phase III
randomised controlled trials and those recruiting patients with breast cancer. A list of indicators of cancer trial
impact was generated using the previous literature and developed inductively using these case studies. The most
common impact from a cancer trial identified in the case studies was on policy, in particular citation of trial findings
in clinical guidelines. Impact on health outcomes and the economy were less frequent and health outcomes were
often predicted rather than evidenced. There were few descriptions identified of trialists making efforts to maximise
trial impact.
Discussion: Cancer trial impact narratives for the next REF assessment exercise in 2021 can be improved by
evidencing actual rather than predicted Impact, with a clearer identification of the beneficiaries of cancer trials and
the processes through which trial results are used. Clarification of the individuals responsible for performing impact
evaluations of cancer trials and the provision of resources to do so needs to be addressed if impact evaluation is to
be sustainable.
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Introduction
The success of a modern cancer trial should not be de-
termined solely by the trial results or the impact factor
of the journal of publication. In addition, this success
should be based on the real-life benefits that the trial
makes to patients and society. Several institutions that
fund or perform cancer trials, including Cancer Research
UK, the Institute of Cancer Research and the Dana-
Farber Cancer Institute, have formally endorsed the San
Francisco Declaration on Research Assessment [1]. This
declaration states that the evaluation of scholarly output
should focus on meaningful benefits arising from re-
search rather than narrow, quantitative metrics.
Cancer trials attract substantial investment from pub-
lic and private funding. In 2019, the National Cancer In-
stitute received over US$6 billion from Congress to fund
cancer research, with over US$800 million spent on clin-
ical trials [2, 3]. Cancer Research UK, which is the single
largest funder of cancer research in the United Kingdom
(UK), spent £546 million on cancer research in 2018/
2019 [4], has pledged £45 million specifically to its eight
clinical trials units and [5] recruits over 25,000 patients
to its clinical trials per annum [6].
In order to show accountability for these investments
and to demonstrate to the public that money is invested
wisely, it is crucial to show that academic outputs from
cancer trials are leading to broader changes and benefits
to society. These benefits are commonly referred to as
the impact of research. The UK Higher Education Fund-
ing Council for England states that impact is ‘an effect
on, change or benefit to the economy, society, culture,
public policy or services, health, the environment or
quality of life, beyond academia’ [7].
Demonstrating the real-life impact of cancer trials can
illustrate to patients and the public the value of partici-
pating in clinical trials. Outlining to healthcare managers
the benefits that cancer trials bring to the health system
may increase the time allocated to clinicians for trial re-
cruitment. Demonstrating to funders that trials are im-
pactful and identifying which types of trial have most
impact means that funders can prioritise clinical trial in-
vestment. This is important because there is an oppor-
tunity cost that accompanies the decision to develop and
perform one trial rather than another, due to the limited
pool of patient volunteers and administrative support
available. For example, Carlisle et al. [8] have demon-
strated that clinical trials of cancer monotherapy con-
ducted in the post-regulatory approval setting contribute
less to subsequent drug approval and clinical guidelines
than trials conducted for approval purposes. This is des-
pite an at least equivalent burden for patients in terms
of numbers needed for recruitment and the proportion
who experience serious adverse events related to trial
treatment. Only by understanding the impact of previous
trials can funders, policy-makers and clinicians design,
prioritise and invest in increasingly impactful trials in
future.
Although the evaluation of research quality is not new,
the assessment of research impact is a more recent
phenomenon. The UK Government allocates research
funding to higher-education institutions based on an as-
sessment of the institutions’ previous research efforts.
This allocation has traditionally focussed on an assess-
ment of institutions’ journal publications and the re-
search environment and prior to 2014 (1986–2008), was
known as the Research Assessment Exercise. For the
first time in 2014, allocation of funding was also
dependent on an evaluation of the wider, societal impact
from research. The name of the assessment was changed
to the Research Excellence Framework (REF), and, in the
exercise conducted in 2014 (REF2014), assessment of re-
search impact was performed by evaluation of case stud-
ies. Impact case studies are narratives written by the
institutions to describe the downstream effects that the
institution perceive to represent the wider, societal im-
pact related to their research, that is external to aca-
demia. The REF was piloted in the UK in 2010, formally
employed in 2014, and the next assessment is due in
2021. Through this exercise the government allocates
over £2 billion per annum to higher-education institu-
tions and in 2021, impact case studies will attract an
even greater proportion of funds (25%) compared to
2014 (20%). Partly because of the REF, the ability of UK
universities to demonstrate that their research has led to
real-life, tangible benefits to society, has become a major
determinant of core income and status for these institu-
tions. Other countries, such as Australia and Canada,
are now (re-) investigating the use of impact assessment
as part of their national evaluation frameworks [9, 10].
Several authors have reflected on how universities evi-
denced the impact of their research in the REF2014.
Greenhalgh and Fahy [11] outlined 14 types of impact
evidenced by higher-education institutions in 162 impact
case studies submitted to the REF2014 community-
based disciplines’ panel. They found that an influence on
guidelines was most commonly described, followed by
impact on informing policy change and changes in clin-
ical or public health practice. Chowdhury, Koya and
Philipson [12] reviewed 363 case studies in six disci-
plines from either top-ranking or bottom-performing in-
stitutions in the REF2014 and identified variables that
predicted the average REF scores received by the institu-
tions. For 92 case studies submitted under the discipline
of Clinical Medicine, the number of publications in
highly cited journals was the variable most consistently
associated with higher REF scores. These authors also
used automated word frequency analysis to identify
themes of research submitted under different disciplines.
Hanna et al. Trials          (2020) 21:486 Page 2 of 13
For clinical medicine, these included oncology, paediat-
rics, genetics, diabetes and heart disease research. Ter-
ämä et al. [13] used computational text-mining of the
REF2014 case studies to understand how higher-
education institutions interpreted impact. By analysing
6637 case studies, six classes of impact were identified (1
– Education, 2 – Public engagement, 3 – Environment
and energy solutions, 4 – Enterprise, 5 – Policy; 6 – Clin-
ical uses) and the class of impact described differed ac-
cording to discipline. Similarly, a review of the REF2014,
commissioned by the Higher Education Funding Council
for England, discovered that frameworks and taxonomies
of impact were often context specific [14].
The aim of this paper was to use the REF2014 case
studies to understand how higher-education institutions
evidenced the impact of their cancer trials. Such an un-
derstanding will allow reflection on if, and how, impact
assessment for cancer trials can be performed outside
the context of the REF, and how impact evaluation can
improve, both for REF2021 and beyond.
The objectives were:
 To identify cancer trials included by higher-
education institutions in the REF2014 case studies
 To quantify and explore the characteristics of these
trials and the types of impacts they were claimed to
have had
 To identify the types of evidence used by higher-
education institutions to substantiate those claims of
impact
 To identify any examples of researchers or research
users making active attempts to maximise impact
Methods
Data collection
The REF2014 impact case studies are stored online and
are publicly available via the Research Excellence Frame-
work 2014 website [15]. A search of the non-confidential
case studies was performed by combining the terms
‘cancer’ and ‘trial’ in the website search function [15].
This search function identified case studies that included
these words in any part of the submission (title, main
text or references). The case studies identified were read
in full and the application of inclusion and exclusion cri-
teria at this stage allowed the selection for final analysis.
Inclusion criteria required that the case study focussed
on the impact of adult (aged 16 years or over) clinical
trials that prospectively recruited patients with a diagno-
sis of malignancy, or individuals without a known diag-
nosis but where the aim of the trial was to investigate
the development of, diagnosis or screening of cancer. All
stages of cancer and clinical trials of all phases were in-
cluded. Impact case studies were excluded if they de-
scribed paediatric cancer trials (age < 16 years) and/or if
clinical trials were mentioned but were not the focus of
the case study.
Data analysis
Manual content analysis of the case studies meeting
these criteria was performed [16]. The initial coding
manual was based on previous literature [11, 17–19],
collected descriptive information about the case studies
and cancer trials, and contained pre-defined categories
of impact that were identified from a systematic review
(unpublished). Supplementary material 2 explains in
more detail how these categories of impact were identi-
fied. The manual was developed iteratively through three
stages by two researchers (CH and LG) to better reflect
the specific context of cancer trial impacts. For a de-
tailed outline of the coding process, see Fig. 1b. This
iteration included the inclusion of specific examples,
often referred to as indicators [12], of how higher-
education institutions evidenced impact within each
categories. The second reviewer (LG) coded a ran-
domly selected sub-sample of the case studies to as-
sess coding validity. The final inter-coder reliability
estimate for this was 80.2%.
In Part 1 of the coding manual (Supplementary mater-
ial 1) the following information was recorded: (1) the in-
stitution responsible for the submission; (2) the Unit of
Assessment and (3) the Summary Impact Type. The
Units of Assessment are 36 subject areas, each with its
own REF expert review panel. The Summary Impact
Types are eight categories of impact, assigned to each
case study by text analysis after submission to the REF.
These categories are technological, economic, health,
political, legal, cultural, societal and environmental [13].
For the clinical trials identified, the following key charac-
teristics were extracted: (1) name; (2) phase of the trial;
(3) type of cancer investigated; (4) focus of the trial
(screening, diagnosis and treatment, other); (5) journal
of publication cited in the case study; (6) category of
funder; (7) primary endpoint and (8) whether the pri-
mary endpoint was met. For the purposes of the final
characteristic, trials were marked as positive if they met
their pre-specified primary endpoint with statistical sig-
nificance. For non-inferiority trials, if the experimental
arm of the trial was deemed to be statistically non-
inferior than the control arm at the level of significance
pre-defined by the trialists, this was considered a positive
result. For earlier-phase trials such as phase I trials fo-
cussing on safety, if, for example, the authors set out to
find a recommended phase II dose of a novel drug, and
this was achieved and reporting in the trial findings, this
was considered as having a positive result.
Part 2 of the coding manual (Supplementary material
1) captured the following information for each impact
case study: (1) all categories of impact described; (2)
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examples of dissemination and knowledge transfer of
trial information and results; (3) methods used by in-
stitutions to evidence impact; (4) clinical guidelines
cited and (5) examples of when researchers or re-
search users acted to enhance trial impact [20]. Dis-
semination and knowledge transfer describe the
communication of trial information or results to
stakeholders. This information was collected by read-
ing and manually coding the ‘Details of Impact’ sec-
tion of each case study using Nvivo version 12.1
(2018). The pre-defined categories of cancer trial
impact were (i) ‘New knowledge and immediate re-
search outputs’, (ii)‘Capacity building for future re-
search ’, (iii) ‘Policy and guidelines’, (iv)‘Health sector
services and clinical practice’, (v) ‘Improved health for
patients and public’, (vi)‘Economic’ and (vii) ‘Social
and cultural’ impact. A distinction was made between
those case studies in which institutions’ described po-
tential health impacts versus those in which the insti-
tution evidenced health improvements that had
actually occurred; for example, through the use of
audit data or epidemiological studies.
Fig. 1 a Case study selection. b Case study coding
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Results
Impact case studies
Out of 6637 publicly available REF2014 impact case
studies, 234 were returned as potentially relevant based
on the combined word search of “Cancer” AND “Trial”.
On reading the full submissions of these 234 case stud-
ies, 46 met the pre-defined inclusion criteria. Figure 1a
presents the search results in a PRISMA style diagram
[21] and details the reasons for exclusion. The REF Unit
of Assessment, Summary Impact Type and name of in-
stitutions responsible for the submission for each case
study are shown in Table 1.
Characteristics of the cancer trials identified
The number of trials specifically cited in each case study
ranged from 1 to 7. Overall, 106 individual trials were
referenced 110 times. The majority of trials identified
(68%) were phase III randomised clinical trials and most
trials focussed on the treatment of cancer (88%); trials
investigating screening and diagnosis were much less
common at 5% and 4%, respectively. A large proportion
recruited patients with a diagnosis of breast cancer
(35%) (Table 1). The Arimidex, Tamoxifen, Alone or in
Combination (ATAC) trial [22] was discussed in five
separate case studies by four universities [23–27]. The
ATAC trial investigated the efficacy of an orally
administered aromatase inhibitor compared to an orally
administered anti-oestrogen for the adjuvant endocrine
treatment for postmenopausal women with hormone-
receptor-positive, localised breast cancer. When used by
the same university, one case study focussed on the im-
pact on clinical practice change worldwide and the sales
for the drug company responsible for the production of
the aromatase inhibitor [25]. The second focussed on
subsequent research by the same university in response
to knowledge generated from the ATAC trial around
drug-associated bone loss [26]. Impacts described in the
other three ATAC trial case studies included the
provision of tumour specimens for translational research
and investigation of novel biomarkers [27], citation of
the trial results in guidelines with subsequent impact on
clinical practice and breast cancer relapse [24, 27]. The
Prostate Testing for Cancer and Treatment (ProtecT)
trial [28], which was still recruiting at the time of
REF2014 submissions, was described by two universities
as an example of their work [29, 30]. Both institutions
outlined the collaborative approach to designing and
performing this trial and the impact that the background
work for the trial contributed to the concept of active
monitoring for men with prostate cancer and on provid-
ing evidence to support a government decision not to
introduce prostate cancer screening.
As shown in Table 1, there were often collaborative
funding streams for these clinical trials from industry,
the charity sector and government-led research councils.
Figure 2a shows that the journals of publication included
both cancer-specific journals and those aimed at a more
generic clinical readership. The most common primary
outcomes evaluated were overall or cancer-specific sur-
vival (18%; 20/110) or a measure of disease recurrence
or progression (18%; 20/110). Several trials used a co-
primary endpoint (16%; 18/110). Although most trials
(78%; 86/110) met their primary endpoint, one fifth of
trials (20%; 22/110) did not and, for a minority of the tri-
als (2%; 2/110) this was unclear.
Categories of cancer trial impact
The frequency with which different categories of impact
were identified in the case studies are shown in Table 2.
Most case studies (93%) described the impact of cancer
trials on policy, and in particular, the citation of trial re-
sults in national or international clinical guidelines. A
list of the ten clinical guidelines in which these trials are
most cited is in Fig. 2b. None of the case studies referred
to social or cultural impacts of clinical trials. One case
study did explain that a clinical trial had changed ‘cul-
ture and behaviour’, but on reading the narrative this
was coded as a change in the prescribing practice of cli-
nicians [31]. Another case study [32] discussed differ-
ences in cancer screening uptake between different
socioeconomic groups which was partly identified by a
clinical trial and has led to funding for a future trial to
investigate and tackle this problem. There is potential
for this subsequent trial to have substantial social impact
if it successfully identifies ways to address this screening
uptake imbalance.
Dissemination and knowledge transfer
Overall, half (50%, 23/46) of case studies mentioned at
least one type of dissemination or knowledge transfer.
These examples were divided into a description of the
publication of trial results in an academic journal (20%
of case studies; 9/46), citation of the results publication
in other academic articles (7%; 3/46) or other methods
of communication (35%; 16/46) such as reports in the
lay or social media, patient-facing websites and confer-
ence presentations.
Methods of evidencing cancer trial impact
Common methods used by higher-education institutions
to evidence the cancer trial impacts that were identified
included: (1) identification of citations of trial publica-
tions in policy documents (78%; 36/46); (2) interrogation
of real-life patient- or population-level data on clinical
practice or health-service use (52%; 24/46); (3) the use of
expert or user testimony (30%; 13/46) and (4) surveys
(both quantitative and qualitative) (15%; 7/46). Interest-
ingly, testimonies were only from researchers and
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Table 1 Key characteristics of included case studies and trials
Case studies (n = 46) Number Percentagec
Research Excellence Framework (REF) impact typea
Health 37 80%
Technological 8 17%
Political 1 2%
REF Unit of Assessmentb
Clinical Medicine 38 83%
Public Health, Health Services and Primary Care 4 9%
Allied Health Professions, Dentistry, Nursing and Pharmacy 2 4%
Psychology, Psychiatry and Neuroscience 1 2%
Biological Sciences 1 2%
Trials (n = 110)d
Trial focus
Treatment of cancer or its side effects 97 88%
Screening 6 5%
Diagnosis 4 4%
Other (e.g. large observational trial to investigate cancer incidence) 3 3%
Phase of trial
I 17 15%
II 14 13%
III 75 68%
Unknown/other 4 4%
Higher-education institution (n = 19)
University College London 9 20%
Institute of Cancer Research 4 9%
University of Leeds 4 9%
University of Manchester 4 9%
Queen Mary University of London 4 9%
Imperial College London 3 7%
University of Cardiff 2 4%
University of Edinburgh 2 4%
University of Glasgow 2 4%
University of Nottingham 2 4%
University of Oxford 2 4%
University of Birmingham 1 2%
University of Bradford 1 2%
University of Bristol 1 2%
Cardiff University 1 2%
University of Cambridge 1 2%
King’s College London 1 2%
Newcastle University 1 2%
University of Southampton 1 2%
Diagnoses of patients recruited to the included clinical trials (n = 110)d
Breast 38 35%
Gastrointestinal (lower) 15 14%
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funders, with none from policy-makers or patients. Al-
though many (70%; 32/46) case studies described the im-
pact that cancer trials had on changing health outcomes
(Section 5 of the coding manual, Supplementary
material), only seven (15%) described an actual, rather
than predicted or estimated, change in health of patients
(Section 5.1 of the coding manual) (Table 2). Several
(39%; 18/46) case studies specifically quoted the monet-
ary value of the funding linked to the research described
in their case studies, totalling approximately £90 million.
None incorporated this monetary value in an estimation
of the economic return on research investment.
Researchers and research users enhancing cancer trial
impact
A minority (15%; 7/46) of case studies mentioned that
researchers actively enhanced the impact of a clinical
trial. Examples included researchers interacting with
policy-makers to give advice on how to pilot implemen-
tation of clinical trial findings [33] and researchers mak-
ing efforts to ensure that trial findings are presented in
the lay media, health blogs and charity websites [31].
There was also an example of researchers training clini-
cians in the selection of patients who would benefit from
radiotherapy treatment that had been developed in the
context of a clinical trial [34]. The submitting institution
explained that these actions help to ensure implementa-
tion of trial findings and improved uptake of this radio-
therapy treatment in the UK. There was one example of
when a research user enhanced the impact of a cancer
trial. This occurred when a patient used the results from
a cancer trial to lobby the UK government to fund a
novel drug to treat breast cancer for treatment of pa-
tients within the UK [35]. Overall, the fact that there is a
limited number of these examples does not imply that
researchers or research users did not play an important
role in the promotion, implementation and wider impact
of cancer trial findings, but if this did occur, it was not
identified by universities as an important part of their
impact narrative within these case studies.
Discussion
There have been prior reviews of the REF2014 case stud-
ies [19, 36–39], but this is the first analysis that focuses
specifically on cancer research or clinical trials. This
study shows that UK universities recognise cancer trials
as impactful research undertaken at their institutions.
Nineteen (12%) out of 154 institutions participating in
the REF2014 submitted 46 case studies that specifically
focussed on cancer trials. Most of the higher-education
institutions were Russell Group Universities (89%; 16/
19) [40], a self-selected association of 24 leading public
Table 1 Key characteristics of included case studies and trials (Continued)
Case studies (n = 46) Number Percentagec
Haematological 15 14%
Urological 13 12%
Gynaecological 10 9%
Thorax 8 7%
Central nervous system 4 4%
Head and neck (including thyroid) 3 3%
Multiple cancer types 3 3%
Gastrointestinal (upper) 1 1%
Main source of clinical trial funding (n = 110)d
Industry only 33 30%
Charity and Research Council/Government/University 19 17%
Research Council/Government/University only 16 15%
Unknown 14 13%
Charity and Industry 13 12%
Charity, Industry and Research Council/Government/University 8 7%
Charity only 7 6%
aThe Summary Impact Types are eight categories of impact, assigned to each case study by text analysis after submission to the REF. These categories are
technological, economic, health, political, legal, cultural, societal and environmental
bThe Units of Assessment are 36 subject areas, each with its own REF expert review panel. These subject areas are divided into four main panels which group
similar research disciplines. For example, Panel A includes Clinical Medicine and Biological Sciences, Panel B: Chemistry and Physics, Panel C: Law and Economics,
and Panel D: History, Classics and Languages. Each discipline listed within these main panels represents one Unit of Assessment
cMay not add to 100% due to rounding
dEach clinical trial (n = 106) was counted for each individual case study in which it was mentioned (a total of 106 trials mentioned in separate case studies
110 times)
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research universities in the UK, whose member institu-
tions submitted 68% of the highest-ranked (4* outstand-
ing) case studies in the REF2014 [41]. The relatively
small number of universities submitting cancer trial case
studies implies that this type of research is concentrated
at specific locations. Over half (54%) of the case studies
described the impact of more than one trial, raising the
question of whether it is feasible to expect a single trial,
rather than a combination of trials or a programme of
trials’ research, to lead to tangible impacts on patients
and society. Lastly, several universities described the im-
pact of the same trial, illustrating the collaborative ap-
proach adopted at those institutions.
Trials recruiting patients with breast cancer consti-
tuted over a third of the included trials; a much greater
proportion than those recruiting patients with, for ex-
ample, lung cancer (7%). Although breast cancer is the
most common cancer (15% incidence) in men and
women combined in the UK [42], lung cancer has the
highest mortality rate and accounts for over one fifth of
all cancer deaths (2017) [43]. Skin cancer, including mel-
anoma, germ-cell cancer and sarcoma were in the cod-
ing manual but no trials were identified that solely
included patients with these diagnoses. It is likely that,
rather than accurately reflect the relative burden of these
cancers in the UK [44], these case studies reflect the
landmark trials that reported results within the assess-
ment REF2014 eligible period (1993–2014). There were
no trials reporting the benefits of immunotherapy,
widely regarded as a major recent advance in cancer
treatment. Again, it is likely that this reflects the publica-
tion dates of key trials investigating the novel immuno-
therapies and it will be interesting to analyse whether
these trials are in the case studies submitted to the
REF2021. The ten journals in which the clinical trials de-
scribed in these case studies were most frequently pub-
lished all have a Journal Impact Factor over 5 and the
top three have an Journal Impact Factor above 25 [45].
This supports the findings from Chowdhury, Koya and
Philipson [38] that, although not an article-level metric
Fig. 2 a Ten most common journals of trial publication. b Ten most frequently referenced national or international clinical guidelines
Hanna et al. Trials          (2020) 21:486 Page 8 of 13
and not a measure of impact, the research outputs
underlying REF2014 impact case studies were often pub-
lished in journals with a high average citation count.
Higher-education institutions did not exclusively use
clinical trials that met their pre-specified primary end-
points in these case studies as examples of impactful re-
search. For example, the LIBERATE trial [46] closed
early because an increase in breast cancer recurrence
was found to occur in patients being managed with hor-
mone replacement therapy to treat symptoms following
cancer treatment. The submitting university argued that
the impact of this trial was a change in guidelines to pre-
vent subsequent use of hormone replacement therapy
for this group of patients. Another example was the
Table 2 Categories and sub-categories of impact and frequency identified within all 46 case studies
Category/sub-categorya Case study references for this
sub-category (number)
Case study references for this
sub-category (percentage)
1. New knowledge and immediate research outputs 39 85%
1.1 New knowledge generated directly from clinical trial 38 83%
1.2 New knowledge from clinical trial has contributed to a secondary analysis, e.g.
systematic review or meta-analysis
3 7%
2. Capacity-building for future research 24 52%
2.1 Clinical trial has contributed to the development (or intentional ceasing of the
development) of further research, clinical trials and researchers
19 41%
2.2 Clinical trial has led to collaboration and/or data sharing 3 7%
2.3 Clinical trial has led to training of future clinicians and researchers 5 11%
2.4 Clinical trial has led to innovation and novel infrastructure (other than health-
service related), e.g. the development of a novel technique or tool by a commercial
company
4 9%
3. Policy and guidelines 43 93%
3.1 Clinical trial has influence policy agenda setting 7 15%
3.2 Clinical trial has led to a treatment approvals (e.g. drug, device, procedure
licensing or marketing approval)
15 33%
3.3 Clinical trial contributed to clinical guidelines 39 85%
3.4 Clinical trial contributed to other public policy, e.g. government policy 6 13%
3.5 Clinical trial has provided justification of the implementation of existing policy 4 9%
4. Health sector (Health service) 16 35%
4.1 Clinical trial has influenced/benefitted health-service delivery 16 35%
Health sector (Clinical practice) 37 80%
4.2 Clinical trial has changed clinical practice and actual clinical practice has been
evaluated
19 41%
4.3 Clinical trial has changed clinical practice and potential or estimated clinical
practice has been evaluated
30 65%
5. Improved health for patients and public 32 70%
5.1 Clinical trial has contributed to improved health for patients (other than those
in the trial) and actual health changes have been evaluated
7 15%
5.2 Clinical trial has contributed to improved health for patients (other than those
in the trial) and health changes have been estimated
29 63%
6. Economic impact 25 54%
6.1 Clinical trial has led to direct cost savings for the health service 12 26%
6.2 Clinical trial has shown benefit of a diagnostic or management strategy that is
cost-effective
8 17%
6.3 Clinical trial has led to measured or estimated benefits for the macro economy,
e.g. sales of drug for a pharmaceutical company, setting up a new spin-off
company
10 22%
6.4 Clinical trial has led to measured or estimated benefits to the macro economy
from a healthy workforce, e.g. patient returning to work earlier
1 2%
aThe sub-categories are not mutually exclusive and several sub-categories may be coded for each case study. The percentage indicators give the percentage of
the case studies in which this category or sub-category was identified
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FOCUS2 trial [47], which tested the optimal treatment
for elderly and frail patients with metastatic colorectal
cancer. Although the trial did not meet its primary end-
point, it demonstrated the feasibility of recruiting pa-
tients from an often under-researched patient cohort. It
also provided important information around toxicity and
quality of life that has subsequently been cited in clinical
guidelines and changed clinical practice. This demon-
strates that the pathway to impact is not solely dictated
by practice-changing trials, but that practice-affirming
trials may be impactful by preventing harmful variation
in practice [48, 49].
The fact that some institutions used early phase trials
as standalone examples of impactful research shows that
robust examples of real-life impact do not only emerge
from large, later-phase trials. As an example, a portfolio
of trials which demonstrated the safety, optimal dosing
and blood-brain-barrier penetration of a drug for pa-
tients with brain tumours, led to both direct (licensing
of the drug) and indirect impacts (a phase III trial per-
formed at another institution, subsequent introduction
of the drug into routine practice and increased revenue
for the pharmaceutical company) [50]. Another case
study described the impact of early phase trials investi-
gating the use a targeted treatment for patients with
BRCA-associated breast and ovarian cancer. The signifi-
cant improvement in outcomes for this sub-group of pa-
tients meant that these trials directly influenced
international guidelines for genetic testing and led to
further research investment and collaboration with in-
dustry for that institution. Submission guidelines indi-
cate that examples of indirect impact will be welcomed
in the REF2021 [51, 52].
The REF2021 expects that institutions will describe
the process through which impact occurs, including,
where possible, evidence of dissemination leading to im-
pact. Ensuring transparency by informing patients and
the public of the results of research, in particular clinical
trials, is one of the UK’s Health Research Authority’s
major priorities for ethical research practice [53]. It was,
therefore, encouraging that some institutions in
REF2014 described methods of knowledge transfer other
than journal publication. In contrast, although there
were examples of researchers or research users enhan-
cing trial impact, these were identified in only a selection
of case studies. Improved and more frequent descrip-
tions of how trialists engage with end users of clinical
trials to maximise timely trial impact could help submit-
ting institutions to better demonstrate the process
through which impact occurs in the REF2021. Finally,
there was a small number of case studies evidencing ac-
tual impact that has occurred using methods such as the
analysis of national audit data [34] or quantification of
drug sales to indicate practice change [27, 54], or
referencing epidemiological studies to show improved
health outcomes [31]. Describing actual impact presents
significant challenges in terms of timelines and planning,
but gives a much stronger indication of the real-life ben-
efits from cancer trials compared to estimations of po-
tential impacts and it is likely that the former will be
viewed favourably in the REF2021 [51].
Reflecting on the findings of this study provides opti-
mism towards the more routine adoption of cancer trial
impact evaluation, but also highlights challenges going
forward. It is reassuring to see that cancer trials, a type
of applied scientific research, are having real-life benefits
for patients. Looking at the narratives submitted by
higher-education institutions it is clear that impact
evaluation is a useful way to scrutinize and reflect on the
merits of the vast amount of work and investment re-
quired to perform these trials and that institutions have
been able to evidence this real-life impact. In addition,
by paying careful attention to trial impact, it is likely that
this will contribute to better research prioritisation in
the future. What is less clear from this study is who
should be responsible for performing these evaluations,
and if there is an expectation on primary researchers,
such as clinicians, statisticians and health economists, to
adopt this role, or if a new breed of researchers will
emerge to answer this call. Impact assessment requires
the utilisation of methods such as surveys, interviews
and the analysis of large datasets, which are skills that
may not be routinely utilised by cancer trialists. In
addition, preparation of submissions to the REF2014
costs UK higher-education institutions £246 million,
with £55 million spent on impact evaluation. This was a
133% increase from the Research Assessment Exercise in
2008 [55]. If the assessment of real-life cancer trial im-
pact is to become a priority for the government and fun-
ders, provision of resources to perform such evaluations
will need to be addressed either through core funding or
specifically within clinical trial research grants.
Table 3 offers some suggestions of how to better
evaluate, communicate and maximise cancer trial impact
in the future. Whether trialists will hold responsibility
for impact assessment or not, articulating the expected
impact of a trial during the design phase, in collabor-
ation with patients, will make subsequent impact evalu-
ation easier and may focus trial design to address unmet
needs. Tracking the impact of clinical practice on a na-
tional level will require access to routinely collected
healthcare data, with sufficient granularity to make
meaningful claims regarding the evidencing of impact
and the identification of barriers to impact. Although
the REF2014 website offers a list of impact case studies
from many disciplines, it would be more useful if future
impact narratives relating to cancer trials were to be
publicised on more clinician- and patient-friendly
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platforms. Opening dialogue about research impact in a
way that resonates with funders and trialists may en-
courage trial design with a focus on longer-term out-
comes, such as changes in health or clinical practice, in
a way that actually makes trials more impactful. The
coding manual used in this study (Supplementary mater-
ial 1) may offer a starting point for trialists to consider
how they could embed impact evaluation into the rou-
tine review of their clinical trial outputs.
There are several limitations to our analysis. Firstly, as
with any review of the REF2014 impact case studies,
these case studies were not specifically intended for this
type of secondary analysis. Secondly, although having
content validity for this study, the list of indicators of
impact used to code these case studies (Supplementary
material 1) will not be an exhaustive list of cancer trial
impacts. In addition, for the purposes of this study we
focussed on evaluating impact. Going forward, it would
also be useful to make an assessment of the investment,
both economic and non-monetary, into cancer trials.
This would allow the impact of trials to be contextua-
lised in terms of the investment provided from funders,
and burden for patients from participating in these trials
[8]. Finally, we used a binary assessment to indicate
whether the primary endpoint was met for each trial. In
future, this could be evaluated in greater detail by also
looking at secondary endpoints or widening the evalu-
ation to explore whether a trial met its objective to re-
cruit sufficient patients to answer a clinical question.
Further research is required to understand which types
of impact are important to patients and other stake-
holders and the processes through which cancer trial im-
pact occurs. It will be useful to repeat this exercise using
the REF2021 case studies to identify which cancer trials
conducted during 2000–2020 are regarded as most im-
pactful by higher-education institutions, and to under-
stand whether the methods of impact assessment have
changed. Although not coded for the purposes of this
study, a comparison of the dates of both the clinical trial
and the impact evidenced would be useful. This would
improve understanding of the time taken to achieve im-
pact from UK cancer trials, which has previously been
estimated to be in the order of 15 years for cancer re-
search [56]. A better understanding of time lags specific-
ally for cancer trials would provide insight into when an
analysis of the return in cancer trial investment should
ideally be performed and may identify opportunities to
speed up impact in some scenarios [57].
Table 3 Suggestions for evaluating, communicating and maximising cancer trial impact
Recommendations: Target groupa
Evaluating the impact
of cancer trials
• Educate trialists to anticipate the types of data required to evaluate impact
and the collection methods to acquire this data. For example, surveys of
current practice, accessing routine prescribing datasets
HEIs
Funders
• Use indicators of cancer trial impact (for example, those in supplementary
material) to more routinely identify the wider impacts of future trials and to
describe the impact of completed trials
Trialists
CTUs
HEIs
• Assess how cancer trial results are used by decision-makers. This will create
a narrative of the pathways through which impact occurs (direct and indirect).
This process may uncover unexpected and less clearly defined impacts
Trialists
CTUs
Researchers
HEIs
• Identify examples of researchers or patients actively contributing to maximising
trial impact
Trialists
CTUs
• Evaluate the impact of negative trials. Demonstrating impacts that do not rely
on positive trial results will encourage funders and researchers to adopt a
broader approach to clinical trial output assessment
Trialists
CTUs
• Provide funding and support for robust cancer trial impact evaluation Funders
HEIs
Communicating the impact
of cancer trials
• Publicise cancer trial impact evaluations. Platforms for publicising evaluations
could include patient-facing charity websites, CTU websites and clinical trial
registries as well as more formal channels such as open access publications
Trialists
CTUs
HEIs
Funders
Maximising the impact
of cancer trials
• Incorporate impact assessment into the trial design process. This will generate ideas
for researchers and CTUs of how they can take a more active role in maximising
impact
Trialists
CTUs
• Continue to provide opportunities for trialists to engage with stakeholders, including
patients, in the planning stages of clinical trial design to specifically explore the types
of wider trial impacts that are important to stakeholders
Funders
CTUs
HEI higher-education institution, CTU clinical trials unit
aThe target group will also depend on who is performing the impact evaluation. As highlighted in the manuscript, there may be researchers, distinct from clinical
trialists, who adopt the role of evaluating impact
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This study should be helpful to institutions in any
country who conduct cancer trials, and, in particular, in
the UK as they currently prepare for their REF2021 sub-
missions. It will also allow cancer trial funders to con-
textualise responses received when trialists describe the
actual or potential impact of their work. The results
should help conscientious cancer trialists and cancer
trial units to consider how they can demonstrate the
wider impact of their work to funders and patients. Ul-
timately, a better understanding and more routine adop-
tion of impact assessment will provide the knowledge
and vision required to ensure that we are conducting
meaningful cancer trials research for patients.
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